Saturday, December 20, 2014 11:34:12 AM
Hope Iluvien works as promised, my niece could really benefit from this. Diabetic from age 10, so sad. Glad to see positive progress!!!
Recent EYPT News
- EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026 • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/27/2026 08:08:02 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/27/2026 08:05:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/20/2026 08:07:36 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/17/2026 08:36:59 PM
- EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/16/2026 08:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/13/2026 08:05:14 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 03/26/2026 10:22:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 08:05:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/20/2026 08:31:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/16/2026 08:12:55 PM
- EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/16/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 09:32:27 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/05/2026 09:06:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 09:02:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2026 12:05:26 PM
- EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments • GlobeNewswire Inc. • 03/04/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/02/2026 12:05:30 PM
- EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular Edema • GlobeNewswire Inc. • 03/02/2026 12:00:00 PM
- EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026 • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 02/24/2026 09:00:49 PM
- EyePoint Announces Participation at Upcoming Investor Conferences • GlobeNewswire Inc. • 02/24/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 09:07:08 PM
- EyePoint Appoints Michael Campbell as Chief Commercial Officer • GlobeNewswire Inc. • 02/18/2026 12:00:00 PM
